Q Bio, a quantitative, clinically-relevant assessment platform for personal human health, announces the collection of $40 million in Series B funding led by Andreessen Horowitz, bringing the total funding to $58 million. This latest round of funding will allow Q Bio to continue to improving its proprietary platform and technology to make their preventive health services faster, better & more affordable for all.

“Since my own misdiagnoses over a decade ago, I’ve imagined a day when everything about a person’s body could be quickly measured, shared and analyzed. It took time but Q Bio was born,” asserts Jeffrey Kaditz, Co-Founder & CEO, Q Bio. “We are thrilled to have our current investors continue to share our vision and excitement for what is possible in the field of preventive health,” he adjoins.

Ideated in 2015 with a mission to empower people gain a deeper understanding of their body and how it’s changing, the company has spent the last few years in stealth mode, focusing on tuning its imaging protocols &

We are thrilled to have our current investors continue to share our vision and excitement for what is possible in the field of preventive health

determining the most clinically-relevant set of biomarkers to include in its platform that can look for existential risks in an asymptomatic population. Within 75 minutes, members are able to get a comprehensive picture of their health & receive a web-based dashboard that they can review from anywhere in the world with their chosen clinicians. The Redwood City based company had quietly opened its doors to a limited membership in late 2019 & plans to open additional locations this year.

Commenting on this development, Vijay Pande, General Partner, Andreessen Horowitz, says, “Q Bio makes true preventive medicine possible today”. He adds to it, “By measuring everything from blood to imaging and more in a longitudinal way, patients can have personalized baselines and physicians the data and power to understand, interpret and utilize this data to personalize care.”

As part of this new round of funding, Pande along with Vinod Khosla from Khosla Ventures will formally join Kaditz on the company’s Board of Directors. Clarissa Shen, who joined Q Bio in 2019 as its COO, will also join as a Board Observer.